Beyond The Tumor: A Review of Standard Procedures and Emerging Advancements in Treatments for Glioblastomas
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6708Keywords:
Glioblastoma, Cancer Treatment, Nanobots, Tumor Treating FieldsAbstract
Glioblastomas are a type of brain tumor, which–according to the Glioblastoma Research Organization–affects more than 241,000 people across the globe. While the causes of glioblastomas are largely unknown, research has shown that some glioblastomas arise likely due to genetic factors such as mutations in isocitrate dehydrogenase (IDH) gene or a 9p/13q deletion. Glioblastomas are extremely hard to treat because they rapidly proliferate, and spread into nearby brain tissues. Surgery has long been used to remove glioblastomas, in order to minimize the intracranial pressure due to the growth of tumor and to reduce tumor bulk for other therapies. However, surgical removal has been tough, since it is very hard to remove all the cancerous cells, and there is a high chance of tumor recurrence. In 2005, the FDA approved the drug temozolomide to be used in glioblastoma treatment following surgical removal. However, temozolomide is minimally effective and causes adverse effects in many patients. As of now, there is no real cure for glioblastoma. Therefore, there is a need to explore new treatments in order to increase the lifespan of glioblastoma patients, as well as to reduce unwarranted effects due to treatment. Newer treatments such as tumor treating fields and nanobots have shown to be promising for glioblastoma treatments. These new advancements have shown to be more precise, which reduces the concern of toxicity to healthy tissues. By researching various treatments for glioblastomas, this paper’s main goal is to explore alternative ways to treat glioblastomas effectively.
Downloads
References or Bibliography
Arrieta, V. A., Dmello, C., McGrail, D. J., Brat, D. J., Lee-Chang, C., Heimberger, A. B., Chand, D., Stupp, R., & Sonabend, A. M. (2023). Immune checkpoint blockade in glioblastoma: From tumor heterogeneity to personalized treatment. Journal of Clinical Investigation, 133(2). https://doi.org/10.1172/jci163447
Asadi, M.H., Khalifeh, K. & Mowla, S.J. OCT4 spliced variants are highly expressed in brain cancer tissues and inhibition of OCT4B1 causes G2/M arrest in brain cancer cells. J Neurooncol 130, 455–463 (2016). https://doi.org/10.1007/s11060-016-2255-1
Balañá, C., & Vaz, Á. (2021). Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized ... ClinicalTrials.gov. https://ascopubs.org/doi/10.1200/JCO.2013.49.6968
Baldo, B. A., & Pham, N. H. (2013). Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer metastasis reviews, 32(3-4), 723–761. https://doi.org/10.1007/s10555-013-9447-3
Barzegar Behrooz, A., Talaie, Z., & Syahir, A. (2022). Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable. Pharmaceutics, 14(8), 1697. https://doi.org/10.3390/pharmaceutics14081697
Benmelouka, A. Y., Munir, M., Sayed, A., Attia, M. S., Ali, M. M., Negida, A., Alghamdi, B. S., Kamal, M. A., Barreto, G. E., Ashraf, G. M., Meshref, M., & Bahbah, E. I. (2021). Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges. International journal of molecular sciences, 22(5), 2258. https://doi.org/10.3390/ijms22052258
Bhere, D., Choi, S. H., van de Donk, P., Hope, D., Gortzak, K., Kunnummal, A., Khalsa, J., Revai Lechtich, E., Reinshagen, C., Leon, V., Nissar, N., Bi, W. L., Feng, C., Li, H., Zhang, Y. S., Liang, S. H., Vasdev, N., Essayed, W., Quevedo, P. V., Golby, A., … Shah, K. (2022). Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature communications, 13(1), 2810. https://doi.org/10.1038/s41467-022-30558-3
Castellano, A., Cirillo, S., Bello, L., Riva, M., & Falini, A. (2017). Functional MRI for Surgery of Gliomas. Current treatment options in neurology, 19(10), 34. https://doi.org/10.1007/s11940-017-0469-y
Chua, J., Nafziger, E., & Leung, D. (2019). Evidence-Based Practice: Temozolomide Beyond Glioblastoma. Current Oncology Reports, 21(4), 1-9.
Datsi, A., & Sorg, R. V. (2021). Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. Frontiers in immunology, 12, 770390. https://doi.org/10.3389/fimmu.2021.770390
Davis M. E. (2016). Glioblastoma: Overview of Disease and Treatment. Clinical journal of oncology nursing, 20(5 Suppl), S2–S8. https://doi.org/10.1188/16.CJON.S1.2-8
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premiai, A. L. R., Greenbaum, J. A., Cohen, E. E. W., Peters, B., & Schoenberger, S. P. (2023). Linked [CD4.sup.+]/[CD8.sup.+] T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. Journal of Clinical Investigation, 133(17), NA.
https://link.gale.com/apps/doc/A763929738/HWRC?u=light025&sid=bookmark
Eibl, R. H., & Schneemann, M. (2023). Liquid biopsy and glioblastoma. Exploration of targeted anti-tumor therapy, 4(1), 28–41. https://doi.org/10.37349/etat.2023.00121
Fukushima, H., Suzuki, R., Yamaki, Y., Hosaka, S., Inaba, M., Muroi, A., Tsurubuchi, T., Morii, W., Noguchi, E., & Takada, H. (2021). Cancer-predisposition genetic analysis in children with brain tumors treated at a single institution in Japan. Oncology, 100(3), 163–172. https://doi.org/10.1159/000521621
Ghiaseddin, A. P., Shin, D., Melnick, K., & Tran, D. D. (2020). Tumor treating fields in the management of patients with malignant gliomas. Current Treatment Options in Oncology, 21(9). https://doi.org/10.1007/s11864-020-00773-5 ]
Hosseinalizadeh, H., Habibi Roudkenar, M., Mohammadi Roushandeh, A., Kuwahara, Y., Tomita, K., & Sato, T. (2022). Natural killer cell immunotherapy in glioblastoma. Discover. Oncology, 13(1), 113. https://doi.org/10.1007/s12672-022-00567-1
Kamson, D. O., & Grossman, S. A. (2021). The role of temozolomide in patients with newly diagnosed wild-type idh, unmethylated MGMTp glioblastoma during the COVID-19 pandemic. JAMA Oncology, 7(5), 675. https://doi.org/10.1001/jamaoncol.2020.6732
Kanderi, T., & Gupta, V. (2022). Glioblastoma multiforme - statpearls - NCBI bookshelf. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK558954/
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-oncology, 20(12), 1566–1572. https://doi.org/10.1093/neuonc/noy072
Khan, M., Li, X., Yan, M., Li, Z., Yang, H., & Liao, G. (2021). Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. International journal of general medicine, 14, 5209–5220. https://doi.org/10.2147/IJGM.S323576
Kumthekar, P., Ko, C. H., Paunesku, T., Dixit, K., Sonabend, A. M., Bloch, O., Tate, M., Schwartz, M., Zuckerman, L., Lezon, R., Lukas, R. V., Jovanovic, B., McCortney, K., Colman, H., Chen, S., Lai, B., Antipova, O., Deng, J., Li, L., Tommasini-Ghelfi, S., … Stegh, A. H. (2021). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science translational medicine, 13(584), eabb3945. https://doi.org/10.1126/scitranslmed.abb3945
Larsson SC, Carter P, Kar S, Vithayathil M, Mason AM, Michaëlsson K, et al. (2020) Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med 17(7): e1003178. https://doi.org/10.1371/journal.pmed.1003178
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & development, 29(12), 1203–1217. https://doi.org/10.1101/gad.261982.115
Lombardi, M. Y., & Assem, M. (2017). Glioblastoma genomics: A very complicated story - glioblastoma - NCBI ... National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK470004/
Luksik, A. S., Yazigi, E., Shah, P., & Jackson, C. M. (2023). CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers, 15(5), 1414. https://doi.org/10.3390/cancers15051414
Mann, J., Ramakrishna, R., Magge, R., & Wernicke, A. G. (2018). Advances in Radiotherapy for Glioblastoma. Frontiers in neurology, 8, 748. https://doi.org/10.3389/fneur.2017.00748
Mayo Foundation for Medical Education and Research. (2022, October 25). Brain metastases. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/brain-metastases/symptoms-causes/syc-20350136#:~:text=Brain%20metastases%20may%20form%20one,changes%2C%20memory%20loss%20and%20seizures.
Michael, J. S., Lee, B. S., Zhang, M., & Yu, J. S. (2018). Nanotechnology for Treatment of Glioblastoma Multiforme. Journal of translational internal medicine, 6(3), 128–133. https://doi.org/10.2478/jtim-2018-0025
Murphy, J. (2021, November 24). Mini Optical Fiber Device may boost cancer treatment success. Laser Focus World. https://www.laserfocusworld.com/fiber optics/article/14214166/mini-optical-fiber-device-may-boost-cancer-treatment-success
Osuka, S., & Van Meir, E. G. (2017). Overcoming therapeutic resistance in glioblastoma: The way forward. Journal of Clinical Investigation, 127(2), 415–426. https://doi.org/10.1172/jci89587
Otto-Meyer, S., Lumibao, J., Kim, E., Ladomersky, E., Zhai, L., Lauing, K. L., Scholtens, D. M., Penedo, F., Amidei, C., Lukas, R. V., & Wainwright, D. A. (2019). The interplay among psychological distress, the immune system, and brain tumor patient outcomes. Current Opinion in Behavioral Sciences, 28, 44–50. https://doi.org/10.1016/j.cobeha.2019.01.009
Patterson, J. D., Wongsurawat, T., & Rodriguez, A. (2020). A Glioblastoma Genomics Primer for Clinicians. Medical research archives, 8(2), 10.18103/mra.v8i2.2034. https://doi.org/10.18103/mra.v8i2.2034TTFields
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C., Al-Tamimi, Y., & Collis, S. J. (2021). Tumour treating fields therapy for glioblastoma: current advances and future directions. British journal of cancer, 124(4), 697–709. https://doi.org/10.1038/s41416-020-01136-5
Sadik, Z. H. A., Hanssens, P. E. J., Verheul, J. B., Beute, G. N., Te Lie, S., Leenstra, S., & Ardon, H. (2018). Gamma knife radiosurgery for recurrent gliomas. Journal of neuro-oncology, 140(3), 615–622. https://doi.org/10.1007/s11060-018-2988-0
Sales, A. H. A., Beck, J., Schnell, O., Fung, C., Meyer, B., & Gempt, J. (2022). Surgical Treatment of Glioblastoma: State-of-the-Art and Future Trends. Journal of clinical medicine, 11(18), 5354. https://doi.org/10.3390/jcm11185354
Scheck, A. C., Perry, K., Hank, N. C., & Clark, W. D. (2006). Anticancer activity of extracts derived from the mature roots of scutellaria baicalensis on human malignant brain tumor cells. BMC Complementary and Alternative Medicine, 6(1). https://doi.org/10.1186/1472-6882-6-27 https://link.gale.com/apps/doc/A748826985/HWRC?u=light025&sid=bookmark HWRC&xid=278c083f
Segura-Collar, B., Hiller-Vallina, S., de Dios, O., Caamaéo-Moreno, M., Mondejar-Ruescas, L., Sepulveda-Sanchez, J. M., & Gargini, R. (2023). Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators. Acta Neuropathologica Communications, 11(1), NA.
Singh, A. V., Chandrasekar, V., Janapareddy, P., Mathews, D. E., Laux, P., Luch, A., Yang, Y., Garcia-Canibano, B., Balakrishnan, S., Abinahed, J., Al Ansari, A., & Dakua, S. P. (2021). Emerging application of nanorobotics and artificial intelligence to cross the BBB: Advances in design, controlled maneuvering, and targeting of the barriers. ACS Chemical Neuroscience, 12(11), 1835–1853. https://doi.org/10.1021/acschemneuro.1c00087
Stensjøen, A. L., Solheim, O., Kvistad, K. A., Håberg, A. K., Salvesen, Ø., & Berntsen, E. M. (2015). Growth dynamics of untreated glioblastomas in vivo. Neuro-oncology, 17(10), 1402–1411. https://doi.org/10.1093/neuonc/nov029
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu, J. J., Stragliotto, G., Tran, D., Brem, S., Hottinger, A., Kirson, E. D., Lavy-Shahaf, G., Weinberg, U., … Ram, Z. (2017). Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA, 318(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718
Testa, U., Castelli, G., & Pelosi, E. (2018). Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Medical Sciences, 6(4), 85. MDPI AG. Retrieved from http://dx.doi.org/10.3390/medsci6040085
Wang, L., Liang, B., Li, Y. I., Liu, X., Huang, J., & Li, Y. M. (2019). What is the advance of extent of resection in glioblastoma surgical treatment-a systematic review. Chinese neurosurgical journal, 5, 2. https://doi.org/10.1186/s41016-018-0150
Wang, G., & Wang, W. (2022). Advanced Cell Therapies for Glioblastoma. Frontiers in immunology, 13, 904133. https://doi.org/10.3389/fimmu.2022.904133
Wang, W., Wu, Z., & He, Q. (2020). Swimming nanorobots for opening a cell membrane mechanically. VIEW, 1(3). https://doi.org/10.1002/viw.20200005
Weenink, B., French, P. J., Sillevis Smitt, P. A. E., Debets, R., & Geurts, M. (2020). Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers, 12(3), 751. https://doi.org/10.3390/cancers12030751
Xu, X., Li, L., Luo, L., Shu, L., Si, X., Chen, Z., Xia, W., Huang, J., Liu, Y., Shao, A., & Ke, Y. (2021). Opportunities and challenges of glioma organoids. Cell communication and signaling : CCS, 19(1), 102. https://doi.org/10.1186/s12964-021-00777-0
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J., … Rabadan, R. (2019). Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature medicine, 25(3), 462–469. https://doi.org/10.1038/s41591-019-0349-y
Published
How to Cite
Issue
Section
Copyright (c) 2024 Anargya Ramamoorthy; Dr. Prahlad Parajuli, Jothsna Kethar, Virgel Torremocha
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
